Quantification of stromal reaction in breast carcinoma and its correlation with tumor grade and free progression survival

Xavier Catteau1,2*, Philippe Simon3, Michel Jondet4, Michel Vanhaeverbeek5, Jean-Christophe Noël2

1 Pathology Department, CUREPATH (CHU Tivoli, Chirec), Jumet, Belgium, 2 Pathology Department, Erasme University Hospital-Université Libre de Bruxelles, Brussels, Belgium, 3 Gynaecologic Department, Erasme University Hospital-Université Libre de Bruxelles, Brussels, Belgium, 4 Gynaecologic Pathology Laboratory, Paris, France, 5 Laboratory of Experimental Medicine, Centre Hospitalo-Universitaire de Charleroi, Montigny-Le-Tilleul, Belgium

* These authors contributed equally to this work.

Abstract

Cancer progression results from a complex interplay between tumor cells and the extracellular milieu. In breast carcinoma, the stromal microenvironment has been suggested to play a major role in promoting tumor growth, progression, and invasion. The stroma of 154 resected specimens of invasive breast carcinoma of no special type was quantified using a digital image analyzer. Statistical analyses were performed between the quantity of stroma and survival, as well as between progression-free survival and clinicopathological data. Levels of myofibroblastic stroma varied from 0–46%, with a median of 15.1% and a standard deviation of 7.5. The myofibroblastic stromal reaction was statistically greater in grade 2 and 3 tumors (p = 0.029). Furthermore, there was a trend for worse progression-free survival in the group of node-negative tumors with strong smooth-muscle actin stromal expression (Log rank = 0.075). The present study demonstrates that the myofibroblastic reaction of breast invasive carcinoma of no special type is not merely a passive reaction, but seems to be an integral part of the neoplastic process by facilitating tumor progression and invasion. Additional, larger studies on mechanisms of stromal change are needed and may potentially lead to novel treatments.

Introduction

Cancer progression results from a complex interplay between tumor cells and the extracellular milieu. The influence of the microenvironment is of critical importance for the invasiveness of cancer cells [1, 2]. In breast carcinoma, the stromal microenvironment has been suggested to promote tumor growth, progression and invasion [3–5]. Indeed, in a previous study, we showed that peritumoral myofibroblasts expressing smooth-muscle actin (SMA) play a role in ductal carcinoma in situ (DCIS) and invasive carcinoma of no special type (CaNST) [6, 7].
Myofibroblasts are a kind of carcinoma-associated fibroblast (CAF) that modulates the stroma in physiological and pathological conditions through both direct cellular contact and through secretion of different components, such as proteinases, extracellular matrix (ECM) elements, and growth factors [7].

The human eye is limited in the interpretation of histological slides. Hence, computer-aided quantitative digital image analysis (DIA) enables a more complete evaluation of different components [8, 9]. Nevertheless, this technique is not commonly used because it is not widely accessible and is time-consuming.

The aim of the present study was to quantify the tumor stroma in invasive carcinoma of no special type (CaNST) using computer-aided quantitative DIA.

Materials and methods

Study population

Breast tumor tissue was retrospectively collected from consecutive patients who were identified through the Pathology Department of Erasme Hospital between July 1997 and November 2002. This study was performed on 154 resected specimens of CaNST. All patients were female. The study protocol was approved by the institutional ethics and research review boards at Erasme Hospital. Patients signed a written informed consent upon admission to the hospital. Patients chose at admission whether to opt in or to opt out of providing consent, which affirms that physicians have the right to use patients’ surplus biological material for research. Consent has been established by the local ethics committee (ethics committee Erasme-ULB, registration number 406) and is in accordance with Belgian and International law (Helsinki declaration).

All archived specimens were reexamined independently by two pathologists (XC, JCN) to confirm the histologic subtype (according to World Health Organization classification). Final pathological tumor stage was determined using the TNM staging system (AJCC Cancer Staging Manual, 8th edition, 2017) and graded using the Nottingham system [10]. For each patient, the following parameters, including patient age, tumor size and grade, TNM classification, lymph node involvement, estrogen receptor (ER) status, progesterone receptor (PR) status, HER2 status and molecular subtypes, were assessed and are summarized in Table 1.

Survival data were collected prospectively and included overall survival (OS) and progression-free survival (PFS), defined as the interval from the date of primary treatment to the first distant recurrence, shown in S1 Table.

Image acquisition

Digitized images of slides were acquired using a Canon 450 EOSD camera. Each case was imaged three or four times at 20X magnification to represent the tumor, and images were saved in JPEG format (3840 x 2820 pixels).

Image analysis

Initial image analysis was performed using the MAMBA Image analyzer (open-source Mathematical Morphology library).

Segmentation to identify objects of interest was performed by adjusting grayscale data to a binary image with foreground pixels of interest set to black and background pixels set to white. The pixel intensity threshold for classifying all pixels as either foreground or background was automatically defined by the software. Features were extracted by measuring pixel numbers of
any particles in the final image. Features extracted included number of stromal SMA-positive cells and total number of cells. Data points were recorded in pixels and exported to Microsoft Excel alongside clinical outcome data. For each tumor, we obtained the median number of positive stromal SMA cells.

**Immunohistochemistry**

Specimens were fixed in histology-grade 4% buffered formalin. A series of paraffin sections were stained with hematoxylin and eosin, and immunohistochemical detection was performed according to the manufacturer’s protocols using a fully automated immunohistochemical system (Autostainer Link 48 from Dako). The SMA antibody was obtained from DAKO (monoclonal mouse, clone 1A4, catalog number IR00611, DAKO, Denmark).

**Statistical analysis**

The relationship between DIA patterns of SMA and differential clinical and histological features (age, tumor size and grade, lymph node status, luminal classification) was compared using a Chi-squared test. Survival curves for OS or PFS were calculated using the Kaplan-Meier method. Different survival curves were compared using the log-rank method.

XLSTAT version 2015.2.01 (Addinsoft) was used for all calculations. In all statistical tests, \( P < 0.05 \) was considered significant.

**Results**

This study was performed on 154 CaNST, and all patients were female. Age varied from 31–92 years with a mean age of 57 years. Table 1 summarizes the clinical and histological features of the study population.

### Table 1. Clinicopathological data of the study.

|                      | Total cases |
|----------------------|-------------|
|                      | n   | %    |
| Age (years)          |     |      |
| <50                  | 45  | 29.4 |
| ≥50                  | 108 | 70.6 |
| Tumor size (mm)      |     |      |
| ≤20                  | 82  | 53.2 |
| >20                  | 72  | 46.8 |
| Lymph node           |     |      |
| negative             | 83  | 53.9 |
| positive             | 71  | 46.1 |
| Histological grade   |     |      |
| grade 1              | 25  | 16.3 |
| grade 2              | 62  | 40.6 |
| grade 3              | 66  | 43.1 |
| ER/PR status         |     |      |
| negative             | 16  | 10.7 |
| positive             | 134 | 89.3 |
| HER2 status          |     |      |
| negative             | 122 | 81.3 |
| positive             | 28  | 18.7 |
| Molecular subtypes   |     |      |
| luminal A            | 30  | 20   |
| luminal B            | 86  | 57.3 |
| luminal HER2         | 18  | 12   |
| HER2 enriched        | 10  | 6.7  |
| triple negative      | 6   | 4    |

https://doi.org/10.1371/journal.pone.0210263.t001
In all cases, peritumoral stroma appeared fibrous (desmoplastic) upon routine staining with hematoxylin-eosin. Stromal cells were fusiform with spindle-shaped nuclei and did not show nuclear-cytoplasmic atypia.

**DIA stromal SMA expression**

Levels of SMA stroma varied from 0–46%, with a median of 15.1% and a standard deviation of 7.5. Fig 1 shows immunohistochemical staining of SMA in the tumor stroma and the corresponding image obtained with DIA. The myofibroblastic stromal reaction was statistically greater in grade 2 and 3 tumors ($p = 0.029$). Strong myofibroblastic reaction was found in 51.5, 61.03, and 24% of tumors in grades 3, 2 and 1, respectively. In contrast, no significant relationship was observed between SMA stromal expression and other clinicopathological features. Table 2 summarizes these results.

There was a trend for worse PFS in the group of node-negative tumors with strong SMA stromal expression (Log rank = 0.075; Fig 2). There was no difference between OS and myofibroblastic reaction.

**Discussion**

The importance of changes in the microenvironment during tumor progression is being increasingly recognized [11–13]. We demonstrated in this work the appearance of a myofibroblastic reaction in invasive carcinoma of NST. This reaction is present in almost 100% of cases, irrespective of clinical or histological parameters. This phenomenon is therefore almost ubiquitous and more than likely plays an important tumor role, particularly in the invasive process. Furthermore and importantly, this proinvasive action seems to be confirmed by intense expression of SMA myofibroblasts correlating with the presence of lymph node metastasis [14]. Indeed, myofibroblasts may induce the production of proinvasive proteinases in cancer [15]. In addition to their role in wound healing, myofibroblasts also provide proinvasive signals that in combination affect invasion of cancer cells [16,17]. Cross talk between cancer cells and stromal cells may be mediated through direct heterotypic cell-to-cell contacts or through secreted molecules [18].

Previously, we demonstrated the importance and the constancy of SMA stromal expression in ductal carcinoma in situ (DCIS) and CaNST in a semiquantitative manner [6, 14]. In the present study, we analyzed this myofibroblastic reaction using another method of quantification with the help of DIA. This method allowed us to determine median levels of SMA stroma as 15% in CaNST. To the best of our knowledge, this is the first study that shows quantitative data for the stroma in CaNST. The quantity of stroma was highly variable between different tumors (range 0–46%). Our study also highlighted a statistically significant relationship between myofibroblastic reaction and tumor grade. The myofibroblastic reaction was stronger in higher-grade tumors. This finding could explain a more important secretion of pro-myofibroblastic factors, like TGF-β, known to be a major player in the SMA stromal reaction, by “more aggressive” tumor cells [14, 19–21].

We observed a trend for reduced PFS in the group of node negative tumors with strong SMA stromal expression. These data suggests that the SMA stromal reaction is a factor conferring poor prognosis in terms of loco-regional recurrence, and this reaction plays a proinvasive role in the neoplastic process.

In conclusion, the present study and our previous work show that the tumoral myofibroblastic reaction in CaNST is not merely a passive reaction but could be an integral part of the neoplastic process by facilitating tumor progression and invasion. Additional, larger studies
Tumor stroma is an integral part of the neoplastic process of breast carcinoma

Fig 1. Stromal SMA expression. Immunohistochemical staining of SMA in tumor stroma (left side) and the corresponding image obtained with DIA (right side).

https://doi.org/10.1371/journal.pone.0210263.g001
Table 2. Relation of stromal SMA expression and clinicopathological features.

|                  | SMA EXPRESSION |
|------------------|----------------|
|                  | >15%           | ≥5% ≤15% | <5% |
| Age (years)      |                |          |     |
| <50              | 51             | 48       | 9   | p = 0.49    |
| ≥50              | 26             | 16       | 3   |
| Tumor size (mm)  |                |          |     |
| ≤20              | 48             | 33       | 7   | p = 0.55    |
| >20              | 30             | 30       | 5   |
| Lymph node       |                |          |     |
| Negative         | 43             | 35       | 3   | p = 0.11    |
| Positive         | 34             | 27       | 9   |
| Histological grade |            |          |     |
| grade 1          | 6              | 15       | 4   | p = 0.029   |
| grade 2          | 38             | 20       | 4   |
| grade 3          | 34             | 28       | 4   |
| ER/PR status     |                |          |     |
| Negative         | 12             | 7        | 1   | p = 0.68    |
| Positive         | 67             | 56       | 11  |
| HER2 status      |                |          |     |
| Negative         | 58             | 54       | 9   | p = 0.29    |
| Positive         | 17             | 8        | 3   |
| Molecular subtypes |            |          |     |
| luminal A        | 13             | 14       | 3   | p = 0.57    |
| luminal B        | 43             | 37       | 5   |
| luminal HER2     | 10             | 5        | 3   |
| HER2 enriched    | 7              | 3        | 0   |
| triple negative  | 2              | 3        | 1   |

Fig 2. Kaplan-Meier curves for PFS. Kaplan-Meier curves for PFS show a trend for reduced PFS for node-negative tumors with strong myofibroblastic reaction (Log rank: p = 0.075).

https://doi.org/10.1371/journal.pone.0210263.g002

on mechanisms of stromal change are needed and may potentially lead to novel treatment strategies.

Supporting information

S1 Table. Anonymized patient data. Anonymized data to calculate progression free survival according stromal reaction.
(XLSX)
Acknowledgments

We thank Isabelle Fayt for her technical work and processing slides.

Author Contributions

Conceptualization: Xavier Catteau, Philippe Simon, Michel Jondet.

Formal analysis: Michel Vanhaeverbeek.

Investigation: Philippe Simon, Jean-Christophe Noël.

Methodology: Michel Jondet, Michel Vanhaeverbeek, Jean-Christophe Noël.

Project administration: Jean-Christophe Noël.

Resources: Philippe Simon, Michel Vanhaeverbeek.

Software: Michel Jondet, Michel Vanhaeverbeek.

Validation: Michel Jondet.

Visualization: Michel Jondet.

Writing – original draft: Xavier Catteau, Michel Jondet, Jean-Christophe Noël.

Writing – review & editing: Xavier Catteau, Jean-Christophe Noël.

References

1. Bates AL, Pickup MW, Hallett MA, Dozier EA, Thomas S, Fingleton B. Stromal matrix metalloproteinase 2 regulates collagen expression and promotes the outgrowth of experimental metastases. J Pathol. 2015; 235:773–783. https://doi.org/10.1002/path.4493 PMID: 25469981

2. Catteau X, Simon P, Noël JC. Myofibroblastic reaction is a common event in metastatic disease of breast carcinoma: a descriptive study. Diagn Pathol. 2014; 9:196. https://doi.org/10.1186/s13000-014-0196-6 PMID: 25399426

3. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004; 432:332–337. https://doi.org/10.1038/nature03096 PMID: 15549095

4. De Wever O, Van Bockstal M, Mareel M, Hendrix A, Bracke M. Carcinoma-associated fibroblasts provide operational flexibility in metastasis. Semin Cancer Biol. 2014; 25:33–46. https://doi.org/10.1016/j.semcancer.2013.12.009 PMID: 24406210

5. Hinz B, Phan SH, Thannickal VJ et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol. 2012; 180:1340–1355. https://doi.org/10.1016/j.ajpath.2012.02.004 PMID: 22387320

6. Catteau X, Simon P, Vanhaeverbeek M, Noël JC. Variable stromal periductular expression of CD34 and smooth muscle actin (SMA) in intraductal carcinoma of the breast. PLoS One. 2013; 8:e57773. https://doi.org/10.1371/journal.pone.0057773 PMID: 23469238

7. Catteau X, Simon P, Noël JC. Myofibroblastic reaction is a common event in metastatic disease of breast carcinoma: a descriptive study. Diagn Pathol. 2014; 9:196. https://doi.org/10.1186/s13000-014-0196-6 PMID: 25399426

8. Hanna MG, Pantanowitz L, Evans AJ. Overview of contemporary guidelines in digital pathology: what is available in 2015 and what still needs to be addressed. J Clin Pathol. 2015; 68:499–505. https://doi.org/10.1136/jclinpath-2015-202914 PMID: 25979986

9. Gurcan MN, Boucheron LE, Can A, Madabhushi A, Rajpoot NM, Yener B. Histopathological image analysis: a review. IEEE Rev Biomed Eng. 2009; 2:147–171. https://doi.org/10.1109/RBME.2009.2034865 PMID: 20671804

Tumor stroma is an integral part of the neoplastic process of breast carcinoma
10. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19:403–410. PMID: 1757079

11. Weinberg R, Mihich E. Eighteenth annual pezcoller symposium: tumor microenvironment and heterotypic interactions. Cancer Res. 2006; 66:11550–11553. https://doi.org/10.1158/0008-5472.CAN-06-3149 PMID: 17158190

12. Bissell MJ, Kenny PA, Radisky DC. Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes. Cold Spring Harb Symp Quant Biol. 2005; 70:343–356. https://doi.org/10.1101/sqb.2005.70.013 PMID: 16869771

13. Tlsty TD, Hein PW. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev. 2001; 11:54–59. PMID: 11163151

14. Catteau X, Simon P, Noël JC. Myofibroblastic stromal reaction and lymph node status in invasive breast carcinoma: possible role of the TGF-β1/TGF-βR1 pathway. BMC Cancer. 2014; 14:499. https://doi.org/10.1186/1471-2407-14-499 PMID: 25011545

15. De Wever O, Demetter P, Mareel M, Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer. 2008; 123:2229–2238. https://doi.org/10.1002/ijc.23925 PMID: 18777559

16. Powell DW, Mifflin RC, Valenti JD, Crowe SE, Saada JL, West AB. Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol. 1999; 277:C1–9. https://doi.org/10.1152/ajpcell.1999.277.1.C1 PMID: 10409103

17. Orimo A, Tomioka Y, Shimizu Y et al. Cancer-associated myofibroblasts possess various factors to promote endometrial tumor progression. Clin Cancer Res. 2001; 7:3097–3105. PMID: 11595701

18. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol. 2003; 200:429–447. https://doi.org/10.1002/path.1398 PMID: 12845611

19. Gobbi H, Arteaga CL, Jensen RA et al. Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in-situ and invasive carcinomas. Histopathology. 2000; 36:168–177. PMID: 10672063

20. Tan AR, Alexe G, Reiss M. Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer. Breast Cancer Res Treat. 2009; 115:453–495. https://doi.org/10.1007/s10549-008-0184-1 PMID: 18841463

21. Loguillo AF, Nonogaki S, Pasini FS, Osório CA, Soares FA, Brentani MM. Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: association with progression. Oncol Rep. 2010; 23:313–320. PMID: 20043090